Novo Nordisk A/s

This clinical trial is testing an investigational medicine called cagrilintide to see how well it helps people with overweight or obesity lose weight. Participants will receive either cagrilintide or a placebo (an inactive substance) by injection, and their weight change will be …

This phase 3 trial is testing whether an experimental once-daily oral drug called zenagamtide can safely help people with excess body weight lose weight. Around 950 adults aged 18 and older with overweight or obesity will be randomly assigned to receive either zenagamtide or a pl…

This Phase 3 study tests whether a weekly injection called zenagamtide helps Asian adults with overweight or obesity lose weight safely. About 400 participants will receive either the drug or a placebo for several weeks. The main goal is to see how much body weight changes, with …

This early-stage trial tests an experimental oral drug, NNC6022-0004, in healthy adults and people with obesity. The study checks how safe the drug is, how the body processes it, and whether food affects its absorption. Participants receive either the drug or a placebo capsule by…

This Phase 3 trial will test whether a new drug called zenagamtide helps people with obesity lose more weight than the current treatment semaglutide. About 650 adults will receive weekly injections of either zenagamtide, semaglutide, or a placebo. The main goal is to see how much…

This study looks at how well a new once-weekly insulin, called insulin icodec, works for people with type 2 diabetes who are switching from a daily insulin. Researchers will track blood sugar control, treatment satisfaction, and how well patients stick to the new regimen over abo…

This study looks at how well a new insulin called icodec controls blood sugar in adults with type 2 diabetes who are switching from their current daily insulin. About 214 participants in Italy will use icodec as prescribed by their doctor for 22 to 30 weeks. Researchers will meas…

This study tests a once-weekly injection called CagriSema (a mix of cagrilintide and semaglutide) in 80 children and adolescents with type 2 diabetes. The goal is to see if it lowers blood sugar and body weight better than a placebo. The trial lasts about 15 months, with everyone…

This Phase 3 trial tests a new once-weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants receive two weekly shots (active drug plus placebo) to see if the new drug is safe and leads to gr…

This study looks at the safety and effectiveness of Rybelsus, a pill for type 2 diabetes, in everyday medical practice in Korea. About 600 adults will take the medicine as their doctor prescribes, and researchers will track side effects and blood sugar control for 26 weeks. The g…

This study investigates whether UBT251, an experimental drug for overweight or obesity, changes how the body processes other medications like warfarin, caffeine, and midazolam. Researchers will give UBT251 to 44 adults with a BMI between 27 and 39.9, then measure levels of these …

This study investigates whether an experimental drug called UBT251 changes how the body processes oral contraceptives and how quickly the stomach empties. It involves women who cannot become pregnant and have overweight or obesity. The goal is to understand if UBT251 can be safel…

This study asks adults with haemophilia A in Germany to complete an online survey about their preferences for preventive treatments. Participants choose between hypothetical treatment options that vary in effectiveness, safety, and how they are given. The goal is to understand wh…

This study will follow 100 adults with X-linked hypophosphatemia (XLH) who are already taking burosumab. Researchers want to see how phosphate levels change over time and how they relate to bone health and overall disease burden. The goal is to better understand the condition and…

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…